GRABAR LAW OFFICE INVESTIGATES POTENTIAL SHAREHOLDER DERIVATIVE ACTION ON BEHALF OF SHAREHOLDERS OF INDIVIOR PLC (LSE: INDV)

The investigation focuses on whether the Company’s Board of Directors and/or officers breached their fiduciary duties.

On July 24, 2020, it was announced that “Indivior Solutions Pleads Guilty To Felony Charge And Indivior Entities Agree To Pay $600 Million To Resolve Criminal And Civil Investigations As Part Of DOJ’s Largest Opioid Resolution.” The resolutions followed the CEO’s Guilty Plea and $1.4 Billion Settlement with Former Corporate Parent, Reckitt Benckiser.

Indivior Solutions pleaded guilty to a one-count felony information and, together with its parent companies Indivior Inc. and Indivior plc, agreed to pay a total of $600 million to resolve criminal and civil liability associated with the marketing of the opioid-addiction-treatment drug Suboxone. Together with a $1.4 billion resolution with Indivior’s former parent, Reckitt Benckiser Group PLC (RB Group), announced in 2019, and a plea agreement with Indivior plc’s former CEO, Shaun Thaxter, announced last month, the total resolution relating to the marketing of Suboxone is more than $2 billion — the largest-ever resolution in a case brought by the Department of Justice involving an opioid drug.

The Board’s failures caused the Company great financial and reputational harm. Viable claims may exist against Indivior’s Board for breaches of their fiduciary duties and violations of federal securities laws.

Current long-term Indivior shareholders have standing to seek corporate governance reforms, the return of funds from Director and Officer liability policies back to company coffers, and a court approved shareholder incentive award if appropriate.

If you would like to learn more at no cost to you, fill out the form provided or contact us at jgrabar@grabarlaw.com.